CurrentBlue Cross Blue Shield - AlabamaPolicy N/A

Provider-Administered Precertification Drug List

Lists provider‑administered drugs that require precertification when given in provider offices, outpatient facilities, or home health settings; gene therapy/cellular immunotherapy products require precertification in any setting. Also notes limited pharmacy access rules for PEEHIP members.

Policy Summary

PayerBlue Cross Blue Shield - Alabama

PolicyProvider-Administered Precertification Drug List

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionObtain precertification prior to administering listed provider-administered drugs in office, outpatient facility, or home health settings (gene therapy products require PA in any setting).

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

200+drugs listed on the precertification roster (approximate)

Gene Therapy/Cellular Immunotherapyproducts requiring PA in any setting

Avastin (oncology only)Avastin PA limited to oncology indications

Monthlylist update frequency

Lemtrada/Synagis/Spravato

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Precertification and Coverage Rules

Precertification requirement

Covered when ALL of the following are met

Precertification requirements: Drug is on the Provider-Administered Precertification Drug List AND precertification obtained prior to administration

Gene Therapy/Cellular Immunotherapy products (marked '+') require precertification in any place of treatment; Avastin requires PA for oncology indications only.

For PEEHIP members, provider-administered medications listed on the Provider-Administered Precertification Drug List are excluded from access through a specialty pharmacy and must be obtained via buy-and-bill, except for specified exceptions. Lemtrada requires use of a specialty pharmacy, while Synagis and Spravato may be obtained either by buy-and-bill or through a specialty pharmacy. This exclusion applies only to PEEHIP members and the drugs outlined in this policy.

What Providers Must Do

Prior Authorization

Prior Authorization Required

Precertification is required for provider‑administered drugs listed on the Provider‑Administered Precertification Drug List when administered in a provider's office, outpatient facility, or home health setting. Gene therapy and cellular immunotherapy products (marked with a + on the drug list) require precertification when administered in any place of treatment.

Applies to all drugs on the Provider‑Administered Precertification Drug List.
Gene therapy/cellular immunotherapy products (+) require PA in any treatment setting.

Note

Action Required Before Treatment

Providers must obtain precertification prior to administration to avoid claim denials or delays in reimbursement.

Precertification must be secured before the drug is administered in office, outpatient facility, or home health.
Failure to precertify may result in denial of coverage or payment delays.

Documentation Required

Documentation / Precertification

Documentation supporting medical necessity should be submitted with the precertification request. For Gene Therapy/Cellular Immunotherapy products (+), precertification and complete documentation are required regardless of the site of care.

Include indication, prior treatments, relevant clinical records, and any specialty‑therapy specific documentation as requested.
Gene therapy/cellular immunotherapy products marked with + require PA and full documentation in any setting.

Billing Rule

Precertification and Site‑of‑Care Billing Rules

For PEEHIP members, provider‑administered medications in this policy must be obtained through buy‑and‑bill and are excluded from specialty pharmacy access, except Lemtrada (must use specialty pharmacy), and Synagis and Spravato (may be obtained via buy‑and‑bill or specialty pharmacy). For Avastin, PA is required for oncology indications only.

PEEHIP coverage: drugs on this list cannot be accessed through specialty pharmacy — obtain via buy‑and‑bill unless specifically noted.
Lemtrada: specialty pharmacy required for PEEHIP members.
Synagis and Spravato: may be obtained via buy‑and‑bill or specialty pharmacy for PEEHIP members.
Avastin: PA required only for oncology indications.

Settings Requiring Precertification

Billing Rule

Site-of-care precertification requirement

Precertification is required when these drugs are administered in a provider's office, outpatient facility, or home health setting. Gene Therapy/Cellular Immunotherapy products (marked '+') require precertification in any setting.

Applies to provider office, outpatient facility, and home health.
Gene therapy/cellular immunotherapy products require PA regardless of site of care.
For PEEHIP members, listed provider-administered medications are excluded from specialty pharmacy access and must be obtained via buy-and-bill, with specified exceptions (Lemtrada, Synagis, Spravato).

List Flags and Notation

List flags

Gene therapy/cellular immunotherapy flag'+' indicates Gene Therapy/Cellular Immunotherapy product; these products require precertification when administered in any place of treatment.

Avastin oncology note'*' indicates Avastin requires prior authorization only for oncology indications.

List update frequencyProduct list is updated monthly and is subject to change without notice.

PEEHIP specialty pharmacy exceptionFor PEEHIP members, most provider-administered medications on this list are excluded from specialty pharmacy access and must be obtained via buy-and-bill; exceptions: Lemtrada requires specialty pharmacy; Synagis and Spravato may be obtained either by buy-and-bill or specialty pharmacy.

Policy Purpose and Scope

This document is an administrative Provider-Administered Precertification Drug List and is intended to define which provider‑administered drugs require precertification and the settings in which precertification is required; it does not provide clinical practice guidelines or therapeutic indications. Precertification is required when listed drugs are administered in a provider's office, outpatient facility, or home health setting. Products designated as Gene Therapy/Cellular Immunotherapy (marked with a '+') require precertification in any place of treatment. The precertification roster is maintained as the operative administrative list of drugs subject to the Provider-Administered Drug Review Program.